Bioventus Acquires Bioness, Inc.

Accelmed Partners Acquires Bioventus' Bioness Advanced Rehabilitation Business

October 1, 2024

Medical Devices

Bioventus has signed a definitive agreement to sell the Advanced Rehabilitation business of its subsidiary Bioness to private equity firm Accelmed Partners for total cash consideration of $45 million (including up to $20 million in earn-outs). The divestiture reduces Bioventus' annual revenue by about $50 million and allows Bioventus to focus on its core business while Accelmed plans to invest in and expand the Bioness rehabilitation product line.

Bioness Medical Acquires Assets and Business of Harmonic Bionics

June 18, 2025

Medical Devices

Bioness Medical, a neuro-rehabilitation technology company based in Valencia, California, has acquired the assets and business of Austin, Texas–based Harmonic Bionics, a developer of a bilateral upper-extremity robotic exoskeleton. The acquisition expands Bioness's product portfolio into upper-extremity robotics and will complement its existing gait and balance systems once regulatory clearance for the Harmonic device is obtained.

Bioventus Inc. Acquires Misonix, Inc.

July 29, 2021

Medical Devices

Bioventus Inc. entered into a definitive agreement to acquire Misonix, Inc. in a cash-and-stock transaction that values Misonix at approximately $518 million on a fully diluted basis. The deal expands Bioventus' regenerative medicine and surgical solutions portfolio by adding Misonix's minimally invasive ultrasonic technologies and regenerative wound products and is expected to close in the fourth quarter of 2021 subject to customary approvals.

Bioventus Acquires CartiHeal for $500M

August 30, 2021

Medical Devices

Nasdaq-traded Bioventus has elected to exercise its option to acquire Israel-based medical device company CartiHeal following FDA approval of the Agili-C implant, in a deal valued at approximately $500 million. Bioventus plans to work with the CartiHeal team on commercialization and reimbursement activities to bring Agili-C to market.

BioVie Acquires Biopharma Assets of NeurMedix

June 11, 2021

Pharmaceuticals

BioVie Inc. acquired the biopharmaceutical assets of privately held NeurMedix, including NE3107, an orally administered small-molecule inhibitor targeting neuroinflammation and insulin resistance. The deal paid NeurMedix shareholders newly issued BioVie shares and cash at closing, with additional contingent cash and equity payments tied to clinical and regulatory milestones; the acquisition expands BioVie's pipeline into neurodegenerative diseases and oncology.

Equillium Acquires Bioniz Therapeutics

February 16, 2022

Biotechnology

Equillium, Inc. (Nasdaq: EQ) acquired privately held Bioniz Therapeutics, obtaining exclusive worldwide rights to Bioniz's pipeline (BNZ-1, BNZ-2, BNZ-3) and proprietary discovery platform in an all-stock transaction (5,699,492 shares, ~19.3% of Equillium outstanding) plus up to $57.5M in development milestones and up to $250M in sales milestones. The acquisition expands Equillium's immunology capabilities and pipeline, adding complementary clinical-stage cytokine-targeting assets and key research and clinical personnel.